Wachtwoord vergeten?

Aandeel Novacyt PSE:ALNOV, FR0010397232

  • 12,140 19 jan 2021 17:38
  • -0,060 (-0,49%) Dagrange 11,520 - 12,220
  • 1.527.924 Gem. (3M) 2,9M

Waar beleggen jullie nog meer in

2.095 Posts
Pagina: «« 1 ... 64 65 66 67 68 ... 105 »» | Laatste | Omlaag ↓
  1. forum rang 4 Hansvdz 16 juli 2020 14:05

    Sub!et schreef op 16 juli 2020 09:09:


    Last Updated: Jul 15, 2020 7:59 p.m. EDT
    Delayed quote
    0.75 31.51%
    After Hours Volume: 9M

    Gisteren volume : 75 mlj.stuks
    Dus opgelet, niet zonder gevaar !!!!!!!!!!!

    Boxlight Corp. is an education technology company. It develops, sells and services interactive classroom solutions for the global education market. The company designs, manufactures and distributes interactive projectors, flat panel displays, touch projectors, touch boards, and MimioTeach through the Boxlight Group and Genesis brands. The firm provides features and specifications like using pens or fingers as a mouse which allows teacher, moderator or student to write or draw images displayed on the surface. Its customers include schools including K-12 and higher education, enterprise for training purposes, government and healthcare. The company was founded by Herbert Myers and Sloan Myers in 1985 and is headquartered in Lawrenceville, GA.

    Een paar dagen geleden had ik deze al gemeld en toen hebben die een mooie rit gedaan. FTFT heeft ook een mooie premarket.
  2. forum rang 4 Hansvdz 16 juli 2020 14:32

    KC 1965 schreef op 16 juli 2020 14:20:

    Nabriva Therapeutics plc (NBRV)
    NasdaqGS - NasdaqGS Real Time Price. Currency in USD
    Add to watchlist

    Quote Lookup

    0.6650+0.0280 (+4.40%)
    At close: July 15 4:00PM EDT
    1.08 +0.415 (62.41%)
    Before hours: 8:20AM EDT

    Dit is ook een goed voorbeeld van een corona stock. Sinds maart naar onder. Als ik geld over had zou ik zeker deze durven te kopen.
  3. KC 1965 17 juli 2020 04:24

    Sub!et schreef op 16 juli 2020 20:48:


    Up to You !!!

    Ik hoop op een herhaling van gisteren met dit nieuws:

    Nabriva Soars on Agreement With Merck to Distribute Sivextro
    Zacks Equity Research
    ,Zacks•July 16, 2020
    Nabriva Therapeutics plc NBRV announced that it has entered into an exclusive agreement with the subsidiaries of pharma giant Merck MRK to sell and distribute the latter’s anti-bacterial medicine Sivextro (tedizolid phosphate) in the United States and across its certain territories. Financial terms of the deal have been kept under wraps.

    Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible Gram-positive microorganisms in patients aged 12 years and above.

    An oxazolidinone-class antibacterial drug, Sivextro was approved by the FDA in 2014 and is owned by Cubist Pharmaceuticals, a wholly owned subsidiary of Merck.

    Per the agreement, Nabriva will be exclusively responsible for marketing, sales and distribution of Sivextro in the United States until Dec 31, 2023 with renewable three-year extensions. With this deal, the company is looking to create value for its shareholders by adding revenue-generating products to its business.

    Shares of Nabriva surged more than 50% in pre-market trading following the announcement of the deal. However, the stock has plunged 49.6% so far this year against the industry’s increase of 7.8%.

    Per the press release, Nabriva is also engaged with Yardley, PA-based privately held company Amplity Health to provide community-based commercial and sales services for Sivextro and its own antibiotic Xenleta (lefamulin) in the United States.

    We remind investors that the FDA approved Nabriva’s new drug application (NDA) in August 2019 for both intravenous (IV) and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia (CABP).

    Following this nod, Xenleta became the first IV and oral antibiotic monotherapy treatment option approved by the FDA for adults with CABP in nearly two decades. The drug is available for oral (600 mg) as well as IV (150 mg) formulations, both to be administered every 12 hours to patients with CABP for a period of five to seven days.

    Zacks Rank & Other Stocks to Consider

    Nabriva currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the biotech sector include Emergent Biosolutions Inc. EBS, BioMarin Pharmaceutical Inc. BMRN and Unum Therapeutics Inc. UMRX, all presently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

    Emergent’s earnings estimates have been revised 26.7% upward for 2020 and 29.8% for 2021 over the past 60 days. The stock has soared 81.9% year to date.

    BioMarin’s earnings estimates have moved 3.3% north for 2020 and 13.4% for 2021 over the past 60 days. The stock has surged 49.9% year to date.

    Unum Therapeutics’ loss per share estimates have narrowed 46% for 2020 and 82.8% for 2021 over the past 60 days. The stock has skyrocketed 299.9% year to date.

    Breakout Biotech Stocks with Triple-Digit Profit Potential

    The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

    Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

    Continue reading
  4. KC 1965 17 juli 2020 04:27

    Nabriva Therapeutics AG (NBRV)

    Melding aanmaken
    Voeg toe aan Portfolio
    0,840 +0,175 +26,32%
    16/07 - Gesloten. Valuta in USD ( Algemene voorwaarden )
    Nabeurs 1,030 +0,190 +22,619% 1:59:45 - Real-time Data
    Type: Aandeel
    Markt: Verenigde Staten
    ISIN: IE00BYQMW233
    CUSIP: 00BYQMW23
    Volume: 102.391.594 Bied/laat: 1,020 / 1,030 Dagbereik: 0,805 - 1,150
    Nabriva Therapeutics 0,840 +0,175 +26,32%
    Algemeen Grafiek Financiën Technisch Forum
  5. Forecast2006 17 juli 2020 06:25
    Relief Therapeutics doet het goed na dit bericht.

    NeuroRx and Relief Therapeutics announce Data Monitoring Committee determination to continue phase 2/3 trial of RLF-100 for Critical COVID-19

    by Relief Therapeutics | Jul 16, 2020

    With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine
    Data Monitoring Committee determined that so far RLF-100 has generated no drug-related Serious Adverse Events or other safety concerns that would mandate stopping. The study is to continue until the next scheduled data review in four weeks.
    Primary endpoint is established as “Alive and free of Respiratory Failure.”

    Radnor, PA and Geneva July 16, 2020 – NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holdings AG (OTC:RLFTF, SIX:RLF) today announced that the independent Data Monitoring Committee has reviewed the findings in the first 30 patients treated in Fast Track FDA trials of RLF-100 (Aviptadil) in patients with Critical COVID-19 with respiratory failure.

    The study protocol enrolls patients with Critical COVID-19 and Respiratory Failure and randomly assigns them to intravenous RLF-100 or Placebo in the hopes of achieving remission from this most-serious stage of COVID-19. At the committee’s recommendation, the primary endpoint is changed to “alive and free of respiratory failure at 7-10 days.” This change in primary endpoint from mortality at 28 days is driven by the general decrease in mortality with advances in treatment for Critical COVID-19 and by initial observations in the clinical trial.

    This first interim analysis was focused on verifying the apparent safety of the drug in the first 30 patients and the feasibility of the study to reach its endpoint. The committee determined that the study appeared capable of reaching a statistically significant endpoint within its 144 patient sample size and voted for the study to continue until its next scheduled evaluation in four weeks.

    The committee is composed of Prof. Alfred Sommer, MD, MHS, Dean Emeritus of the Johns Hopkins Bloomberg School of Public Health, Prof. Rita Colwell, PhD, former Director of the National Science Foundation, and Congressman, Andy Harris, MD, MHS (MD District 1) a part time Professor of Anesthesia and Critical Care at Johns Hopkins School of Medicine.

    RLF-100 (Aviptadil) received Fast Track designation from the US FDA for the treatment of Critical COVID-19 with respiratory failure. Aviptadil is a synthetic form of human Vasoactive Intestinal Peptide (VIP) which is known to protect the Alveolar Type II cell of the lung from many forms of injury. This cell is critical to transmission of oxygen to the blood and is the site of attack for the Coronavirus.

    “This milestone represents the extraordinary effort of our partners and collaborators at the University of Miami, Houston Methodist Hospital, UC Irvine, and University of Louisville who gave 100% to providing patients with Critical COVID-19 a chance to benefit from a potentially life-saving drug. We thank the members of the Data Monitoring Committee for devoting their valuable time to performing this vital role in helping to evaluate the safety and effectiveness of RLF-100,” said Prof. Jonathan C Javitt, MD, MPH, CEO of NeuroRx and the National Study Chair.

    Details of the study are posted on NCT04311697.

    About RLF-100

    RLF-100 (Aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is primarily concentrated in the lung and is known to protect against a variety of lung injuries. VIP was awarded Orphan Drug Designation in 2001 by the U.S. FDA for treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. The European Medicines Agency awarded orphan drug designation in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis.


    The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.

    Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief Therapeutics also holds a U.S. patent[1] for RLF-100 and proprietary manufacturing processes for its synthesis.
    RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF.

    About NeuroRx, Inc.

    NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.

    Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


    Jonathan C. Javitt, M.D., MPH
    Chief Executive Officer
    NeuroRx, Inc.

    Yves Sagot, Ph.D.
    Relief Therapeutics Holding, SA


    Gloria Gasaatura
    LifeSci Communications

    Kind regards,

  6. kilgore 17 juli 2020 08:15
    FR0013514114 - STOCK

    gisteren +20%
    vandaag aankondiging samenwerking :

    Europlasma wil de olie-industrie
    opruimen Europlasma, expert in oplossingen voor verontreinigingsbeheersing, kondigt een samenwerking aan met het Zuid-Amerikaanse juniorbedrijf Field Intelligence Energy, een opkomende speler in de productie van "groene olie", die binnenkort de vorm aanneemt van een aandeleninvestering tot 49% in een joint venture. De Groep breidt daarmee haar positie als multidisciplinaire speler in de wereldwijde zuivering uit door een nieuwe grote industrie en een nieuw continent te veroveren. De ambitie van deze samenwerking is om zonder uitzondering de plasmatoorts te gebruiken om de vervuilde effluenten en vervuilende stoffen die inherent zijn aan de winning van koolwaterstoffen te vernietigen.
2.095 Posts
Pagina: «« 1 ... 64 65 66 67 68 ... 105 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Novacyt Meer »

Koers 12,140   Verschil -0,06 (-0,49%)
Laag 11,520   Volume 1.527.924
Hoog 12,220   Gem. Volume 2.904.203
19 jan 2021 17:38
label premium


Het laatste advies leest u als IEX Premium-lid

Ontdek Premium
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by Infront. Crypto data by Crypto Compare